The former startup founder and Silicon Valley investor will head the University of Cambridge’s commercialisation arm.
The University of Cambridge has hired a former venture capital investor as chief executive of its technology transfer office.
Jim Glasheen will replace Diarmuid O’Brien, who was promoted to pro vice-chancellor of innovation at the University of Cambridge in April this year.
Glasheen was a general partner at Silicon Valley-based Technology Partners Venture Capital between 2002 and 2018, investing in cleantech and life science companies at all stages.
Most recently, Glasheen was co-founder and president of Clade Therapeutics, a Cambridge, Massachusetts-based company developing cell-based medicines for the treatment of cancer and other diseases. It was formed in 2020 and bought by US biotechnology company Century Therapeutics earlier this year.
Glasheen had co-founded Atalanta Therapeutics, another Massachusetts-based biotechnology company, in 2018.
He also has a background in the university research ecosystem, having worked as executive vice-chancellor of innovation and business development at University of Massachusetts Medical School between 2017 and 2020.
Glasheen completed a post-doctoral fellowship at the University of California, Berkeley, and holds a PhD in biology from Harvard University.
